ArticleEuropean heart journal. Case reports2026
Rare case of young cardiac amyloidosis: difficult diagnostic pathway in routine clinical care.
Article in European heart journal. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Light-chain amyloidosis (AL) is a rare plasma cell disorder characterized by extracellular deposition of misfolded light chains in multiple organs, typically manifesting with non-specific symptoms that result in delayed diagnosis. Cardiac involvement is a major adverse prognostic factor. The incidence peaks around the age of 65, and occurrence in younger individuals is exceptionally rare, further complicating timely recognition. Case summary: We report a 41-year-old female patient who exhibited a 1-year course of progressive heart failure, ultimately diagnosed as AL amyloidosis. The 'red flags' were either overlooked or misattributed to other causes of left ventricular hypertrophy, including hypertrophic cardiomyopathy and Fabry disease, partly due to the patient's atypically young age and family history. The initial suspicion of cardiac amyloidosis was based on advanced cardiac magnetic resonance imaging, which was not immediately available at the time. The initial tissue biopsy result was negative, necessitating an expert re-evaluation with a polarized light microscopy. Laboratory workup for AL amyloidosis revealed non-IgM monoclonal gammopathy of undetermined significance as a preceded plasma cell disorder. Discussion: The diagnosis of AL amyloidosis requires evidence of plasma cell dyscrasia through serum/urine immunochemistry, in addition to the detection and typing of amyloid in tissues. Given the rapid progression of the disease and the poor outcomes observed in the absence of timely targeted therapy, broader laboratory screening for AL amyloidosis should be considered in patients with unexplained hypertrophic phenotype or heart failure, irrespective of age. The improved access to expert multidisciplinary teams through dedicated cardiomyopathy centres is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.